Furio Pacini
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Furio Pacini has a total of 250 co-authors. Here are the top co-authors by number of shared publications:
- Maria Grazia Castagna
University of Siena
15 shared publications - Silvia Cantara
Department of Medical, Surgical and Neurological Sciences, University of Siena, 53100 Siena, Italy
12 shared publications - Rossella Elisei
Department of Clinical and Experimental Medicine, Endocrine Unit, University of Pisa, Pisa, Italy
6 shared publications Maria Grazia Castagna
University of Siena
5 shared publicationsMartin Schlumberger
Gustave Roussy Cancer Campus and University Paris-Saclay, Villejuif, Cedex, France
5 shared publicationsLucia Brilli
Section of Endocrinology, Department of Medical, Surgical and Neurological Sciences, University of Siena, Siena, Italy
4 shared publications
Latest Publications
- 1 January 2023
- Published by Springer Nature
- p. 161-162
On ART, and ART (Ablative Radioiodine Therapy)!
- 9 September 2022
- Published by Elsevier in Best Practice & Research Clinical Endocrinology & Metabolism
- Vol. 37 (1) , 101703
Radioiodine therapy in the different stages of differentiated thyroid cancer
- 9 September 2022
- Published by Elsevier in Best Practice & Research Clinical Endocrinology & Metabolism
- Vol. 37 (1) , 101703
Radioiodine therapy in the different stages of differentiated thyroid cancer
- Open Access
- 25 August 2022
- Published by MDPI AG in Healthcare
- Vol. 10 (9) , 1621
Tackling Thyroid Cancer in Europe—The Challenges and Opportunities
Thyroid cancer (TC) is the most common malignancy of the endocrine system that affects the thyroid gland. It is usually treatable and, in most cases, curable. The central issues are how to improve knowledge on TC, to accurately identify cases at an early stage that can benefit from effective intervention, optimise therapy, and reduce the risk of overdiagnosis and unnecessary treatment. Questions remain about management, about treating all patients in referral centres, and about which treatment should be proposed to any individual patient and how this can be optimised. The European Alliance for Personalised Medicine (EAPM) hosted an expert panel discussion to elucidate some of the challenges, and to identify possible steps towards effective responses at the EU and member state level, particularly in the context of the opportunities in the European Union’s evolving initiatives—notably its Beating Cancer Plan, its Cancer Mission, and its research funding programmes. Recommendations emerging from the panel focus on improved infrastructure and funding, and on promoting multi-stakeholder collaboration between national and European initiatives to complement, support, and mutually reinforce efforts to improve patient care.
- 25 August 2022
- Published by MDPI AG in Healthcare
- Vol. 10 (9) , 1621
Open AccessTackling Thyroid Cancer in Europe—The Challenges and Opportunities
Thyroid cancer (TC) is the most common malignancy of the endocrine system that affects the thyroid gland. It is usually treatable and, in most cases, curable. The central issues are how to improve knowledge on TC, to accurately identify cases at an early stage that can benefit from effective intervention, optimise therapy, and reduce the risk of overdiagnosis and unnecessary treatment. Questions remain about management, about treating all patients in referral centres, and about which treatment should be proposed to any individual patient and how this can be optimised. The European Alliance for Personalised Medicine (EAPM) hosted an expert panel discussion to elucidate some of the challenges, and to identify possible steps towards effective responses at the EU and member state level, particularly in the context of the opportunities in the European Union’s evolving initiatives—notably its Beating Cancer Plan, its Cancer Mission, and its research funding programmes. Recommendations emerging from the panel focus on improved infrastructure and funding, and on promoting multi-stakeholder collaboration between national and European initiatives to complement, support, and mutually reinforce efforts to improve patient care.
- 26 April 2022
- Published by Elsevier in The Lancet Diabetes & Endocrinology
- Vol. 10 (6) , 379-381
Postsurgical radioiodine ablation in low-risk differentiated thyroid cancer
- 26 April 2022
- Published by Elsevier in The Lancet Diabetes & Endocrinology
- Vol. 10 (6) , 379-381
Postsurgical radioiodine ablation in low-risk differentiated thyroid cancer
- Top Cited PapersOpen Access
- 1 February 2022
- Published by Bioscientifica in European Thyroid Journal
- Vol. 11 (1)
2022 ETA Consensus Statement: What are the indications for post-surgical radioiodine therapy in differentiated thyroid cancer?
Modern use of post-operative radioactive iodine (RAI) treatment for differentiated thyroid cancer (DTC) should be implemented in line with patients’ risk stratification. Although beneficial effects of radioiodine are undisputed in high-risk patients, controversy remains in intermediate-risk and some low-risk patients. Since the last consensus on post-surgical use of RAI in DTC patients, new retrospective data and results of prospective randomized trials have been published, which have allowed the development of a new European Thyroid Association (ETA) statement for the indications of post-surgical RAI therapy in DTC. Questions about which patients are candidates for RAI therapy, which activities of RAI can be used, and which modalities of pre-treatment patient preparation should be used are addressed in the present guidelines.
- 1 February 2022
- Published by Bioscientifica in European Thyroid Journal
- Vol. 11 (1)
Top Cited PapersOpen Access2022 ETA Consensus Statement: What are the indications for post-surgical radioiodine therapy in differentiated thyroid cancer?
Modern use of post-operative radioactive iodine (RAI) treatment for differentiated thyroid cancer (DTC) should be implemented in line with patients’ risk stratification. Although beneficial effects of radioiodine are undisputed in high-risk patients, controversy remains in intermediate-risk and some low-risk patients. Since the last consensus on post-surgical use of RAI in DTC patients, new retrospective data and results of prospective randomized trials have been published, which have allowed the development of a new European Thyroid Association (ETA) statement for the indications of post-surgical RAI therapy in DTC. Questions about which patients are candidates for RAI therapy, which activities of RAI can be used, and which modalities of pre-treatment patient preparation should be used are addressed in the present guidelines.
- 7 September 2021
- Published by SAGE Publications in Thyroid®
- Vol. 31 (9) , 1416-1423
Screening of Organ-Specific Autoantibodies in a Large Cohort of Patients with Autoimmune Thyroid Diseases
Background: Autoimmune diseases tend to cluster in the same individual or in families. Four types of autoimmune polyglandular syndromes (APS) have been described based on the combination of endocrine and/or non-endocrine autoimmune diseases. In particular, type-3 APS is defined by the association of an autoimmune thyroid disease (ATD) and other autoimmune diseases and has a multifactorial etiology. The natural history of autoimmune diseases is characterized by three stages: potential, subclinical, and clinical. Methods: To determine the prevalence of organ-specific autoantibodies (anti-adrenal, anti-ovary [StCA], anti-pituitary [APA], anti-parietal cells [PCA], anti-tissue transglutaminase [tTGAb], anti-mitochondrial [AMA], anti-glutamic acid decarboxylase [GADA], anti-nicotinic acetylcholine receptor) in patients with ATD and to define the stage of the disease in patients with positive autoantibodies. From January 2016 to November 2018, 1502 patients (1302 female; age 52.7 ± 14.7 [mean ± standard deviation] years, range 18–86 years) with ATD (1285/1502 [85.6%] with chronic autoimmune thyroiditis and 217/1502 [14.4%] with Graves' disease) were prospectively enrolled. Results: The most common organ-specific autoantibodies were PCA (6.99%) and GADA (2.83%), while the prevalence of the remaining autoantibodies was ≤1%. All autoimmune diseases, but celiac disease, were predominant at the potential stage. Sex, ATD type, smoking habit, and coexistence of other autoimmune diseases correlated with the susceptibility to develop chronic atrophic gastritis (CAG) or autoimmune diabetes mellitus. Conclusions: The association between ATD and CAG was the most common manifestation of type-3 APS, mainly at the potential stage, that could lead to appropriate follow-up for early detection and timely treatment of the disease.
- 7 September 2021
- Published by SAGE Publications in Thyroid®
- Vol. 31 (9) , 1416-1423
Screening of Organ-Specific Autoantibodies in a Large Cohort of Patients with Autoimmune Thyroid Diseases
Background: Autoimmune diseases tend to cluster in the same individual or in families. Four types of autoimmune polyglandular syndromes (APS) have been described based on the combination of endocrine and/or non-endocrine autoimmune diseases. In particular, type-3 APS is defined by the association of an autoimmune thyroid disease (ATD) and other autoimmune diseases and has a multifactorial etiology. The natural history of autoimmune diseases is characterized by three stages: potential, subclinical, and clinical. Methods: To determine the prevalence of organ-specific autoantibodies (anti-adrenal, anti-ovary [StCA], anti-pituitary [APA], anti-parietal cells [PCA], anti-tissue transglutaminase [tTGAb], anti-mitochondrial [AMA], anti-glutamic acid decarboxylase [GADA], anti-nicotinic acetylcholine receptor) in patients with ATD and to define the stage of the disease in patients with positive autoantibodies. From January 2016 to November 2018, 1502 patients (1302 female; age 52.7 ± 14.7 [mean ± standard deviation] years, range 18–86 years) with ATD (1285/1502 [85.6%] with chronic autoimmune thyroiditis and 217/1502 [14.4%] with Graves' disease) were prospectively enrolled. Results: The most common organ-specific autoantibodies were PCA (6.99%) and GADA (2.83%), while the prevalence of the remaining autoantibodies was ≤1%. All autoimmune diseases, but celiac disease, were predominant at the potential stage. Sex, ATD type, smoking habit, and coexistence of other autoimmune diseases correlated with the susceptibility to develop chronic atrophic gastritis (CAG) or autoimmune diabetes mellitus. Conclusions: The association between ATD and CAG was the most common manifestation of type-3 APS, mainly at the potential stage, that could lead to appropriate follow-up for early detection and timely treatment of the disease.
- Open Access
- 19 August 2020
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 105 (11) , e4189-e4190
Response to Letter to the Editor from Edmundo Avila-Hipolito: “Long-Term Effects of Radioiodine in Toxic Multinodular Goiter: Thyroid Volume, Function, and Autoimmunity”
Tania Pilli, Catarina Roque, Francisco Sousa Santos, Gilda Dalmazio, Maria Grazia Castagna, Furio Pacini; Response Letter to the Editor from Edmundo Avila-Hipo
- 19 August 2020
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 105 (11) , e4189-e4190
Open AccessResponse to Letter to the Editor from Edmundo Avila-Hipolito: “Long-Term Effects of Radioiodine in Toxic Multinodular Goiter: Thyroid Volume, Function, and Autoimmunity”
Tania Pilli, Catarina Roque, Francisco Sousa Santos, Gilda Dalmazio, Maria Grazia Castagna, Furio Pacini; Response Letter to the Editor from Edmundo Avila-Hipo
- Open Access
- 29 June 2020
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 105 (8) , e3016-e3017
Does Microscopic Extrathyroidal Extension Confer a Higher Risk of Recurrence in Patients With Well-Differentiated Thyroid Cancer?
Furio Pacini, MD; Does microscopic extrathyroidal extension confer an higher risk of recurrence in patients with well differentiated thyroid cancer?, The Journ
- 29 June 2020
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 105 (8) , e3016-e3017
Open AccessDoes Microscopic Extrathyroidal Extension Confer a Higher Risk of Recurrence in Patients With Well-Differentiated Thyroid Cancer?
Furio Pacini, MD; Does microscopic extrathyroidal extension confer an higher risk of recurrence in patients with well differentiated thyroid cancer?, The Journ
- Open Access
- 22 April 2020
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 105 (7) , e2464-e2470
Long-term Effects of Radioiodine in Toxic Multinodular Goiter: Thyroid Volume, Function, and Autoimmunity
Context Long-term studies evaluating the treatment of toxic multinodular goitre (TMNG) with fixed activities of radioiodine (RAI) are lacking. Objective To describe the effects of 15 mCi on thyroid volume, function and autoimmunity in the long-term. Design and Setting: Population-based, retrospective analysis with up to 12 years of follow-up, held in Siena, Italy. Participants Adult patients (n=153) with TMNG, naïve to RAI. Methods Evaluation of thyroid function, anti-thyroid antibodies and ultrasound scans before and yearly after RAI. Main outcome measures Hyperthyroidism cure, hypothyroidism; volume reduction, nadir and regain; antibody titre change. Results The study revealed mean volume reductions ≥50% 3 years after RAI, the greatest annual reduction was observed during the 1st year (30±17.8%; pst 3 years after treatment, hyperthyroid patients decreased approximately by 50%/year without additional RAI. There was no statistically significant association of antibody titres with thyroid function except for TRAb and hyperthyroidism (p=0.004). At the end of follow-up there were 61.6% euthyroid patients, 11% hyperthyroid (4.8% overt) and 27.4% hypothyroid patients (2.7% overt). Hyperthyroidism was cured in 89%. Conclusions The treatment of TMNG with 15 mCi of RAI induced low hypothyroidism rates while providing high cure rates and significant volume reduction, maintained in the long-term.
- 22 April 2020
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 105 (7) , e2464-e2470
Open AccessLong-term Effects of Radioiodine in Toxic Multinodular Goiter: Thyroid Volume, Function, and Autoimmunity
Context Long-term studies evaluating the treatment of toxic multinodular goitre (TMNG) with fixed activities of radioiodine (RAI) are lacking. Objective To describe the effects of 15 mCi on thyroid volume, function and autoimmunity in the long-term. Design and Setting: Population-based, retrospective analysis with up to 12 years of follow-up, held in Siena, Italy. Participants Adult patients (n=153) with TMNG, naïve to RAI. Methods Evaluation of thyroid function, anti-thyroid antibodies and ultrasound scans before and yearly after RAI. Main outcome measures Hyperthyroidism cure, hypothyroidism; volume reduction, nadir and regain; antibody titre change. Results The study revealed mean volume reductions ≥50% 3 years after RAI, the greatest annual reduction was observed during the 1st year (30±17.8%; pst 3 years after treatment, hyperthyroid patients decreased approximately by 50%/year without additional RAI. There was no statistically significant association of antibody titres with thyroid function except for TRAb and hyperthyroidism (p=0.004). At the end of follow-up there were 61.6% euthyroid patients, 11% hyperthyroid (4.8% overt) and 27.4% hypothyroid patients (2.7% overt). Hyperthyroidism was cured in 89%. Conclusions The treatment of TMNG with 15 mCi of RAI induced low hypothyroidism rates while providing high cure rates and significant volume reduction, maintained in the long-term.
- 18 September 2018
- Published by Springer Nature
- p. 131-135
Radioiodine Ablation: Current Status